Organization
Nanjing Chia-Tai Tianqing Pharmaceutical
5 clinical trials
Clinical trial
A Phase Ib/Ⅱ Study of Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of NTQ1062 Tablets in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic Effect of NTQ1062 Tablets in Chinese Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-20
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated PainStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary CholangitisStatus: Recruiting, Estimated PCD: 2024-06-01